SPRO Spero Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1701108 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY2.5%
TTM net income YoY32.7%
TTM EPS YoY36.7%
Revenue 3-yr CAGR-18.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-67.3%
Net margin-71.0%
FCF margin—
EBITDA margin—
Returns
ROE-216.4%
ROA-35.9%
ROIC (approx.)—
Asset turnover0.51x
Leverage & solvency
Liabilities / assets99.3%
Debt / equity0.00x
Current ratio1.92x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.37x
Accruals ratio13.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $66.80M | $47.98M |
| R&D expense | $38.47M | $96.76M |
| SG&A expense | $21.18M | $23.70M |
| Operating income | $6.31M | -$73.36M |
| Pretax income | $8.83M | -$68.57M |
| Income tax | $261,000 | $0 |
| Net income | $8.57M | -$68.57M |
| EBITDA | $6.31M | -$73.36M |
| EPS (basic) | 0.15 | -1.27 |
| EPS (diluted) | 0.15 | -1.27 |
| Weighted avg. shares (diluted) | 59.04M | 54.04M |
| Balance sheet | ||
| Cash & equivalents | $40.27M | $52.89M |
| Current assets | $67.29M | $107.28M |
| PP&E, net | — | $0 |
| Total assets | $68.92M | $110.54M |
| Current liabilities | $8.87M | $49.07M |
| Total liabilities | $9.90M | $64.42M |
| Shareholders' equity | $59.02M | $46.12M |
| Shares outstanding | 56.41M | 54.59M |
| Cash flow statement | ||
| Operating cash flow | -$12.62M | -$23.44M |
| Financing cash flow | — | $0 |
| Depreciation & amortization | $0 | $2,000 |
| Stock-based compensation | $4.33M | $7.79M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.